Keros reports durable transfusion independence in Phase 2 MDS trial; plans registrational Phase 3

Keros Therapeutics, Inc.

Overall erythroid response 55.6% (45/81) in modified ITT patients; 41.3% (26/63) of TI-evaluable achieved ≥8-week transfusion independence.
Median duration of TI not reached; 42.3% (11/26) of TI responders had responses >1 year, all ongoing as of April 3, 2024.
In MF Phase 2, 60.6% (20/33) of transfusion-dependent patients had reduced transfusion burden; 52.9% (9/17) with large spleens had volume reductions at Week 24.
Preclinical MF model data shows elritercept promotes erythropoiesis, mitigates anemia, and improves muscle mass/function.
Company plans to initiate a registrational Phase 3 trial in lower-risk MDS following positive FDA feedback.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.